Aquestive Therapeutics, Inc. (AQST): Price and Financial Metrics

Aquestive Therapeutics, Inc. (AQST)

Today's Latest Price: $6.72 USD

0.17 (-2.47%)

Updated Dec 2 4:00pm

Add AQST to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

AQST Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AQST is -1.51 -- better than only 4.83% of US stocks.
  • AQST's went public 2.36 years ago, making it older than merely 6.02% of listed US stocks we're tracking.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -3.03 for Aquestive Therapeutics Inc; that's greater than it is for only 4.16% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Aquestive Therapeutics Inc are PRTK, GEVO, SENS, BNFT, and ESTA.
  • AQST's SEC filings can be seen here. And to visit Aquestive Therapeutics Inc's official web site, go to

AQST Stock Price Chart Interactive Chart >

Price chart for AQST

AQST Price/Volume Stats

Current price $6.72 52-week high $9.47
Prev. close $6.89 52-week low $1.41
Day low $6.71 Volume 513,398
Day high $7.00 Avg. volume 888,804
50-day MA $5.71 Dividend yield N/A
200-day MA $5.20 Market Cap 225.93M

Aquestive Therapeutics, Inc. (AQST) Company Bio

Aquestive Therapeutics, Inc. operates as a specialty pharmaceutical company that specializes in the drug delivery technology. The company offers PharmFilm, a drug delivery platform/pharmaceutical dosage form that delivers existing prescription products directly to the bloodstream. It develops, manufactures, and commercializes pharmaceutical films, individual film doses, and finished products for patients, physicians, and caregivers. Aquestive Therapeutics, Inc. was formerly known as MonoSol Rx Inc. and changed its name to Aquestive Therapeutics, Inc. in November 2017. The company was founded in 2000 and is based in Warren, New Jersey.

AQST Latest News Stream

Event/Time News Detail
Loading, please wait...

AQST Latest Social Stream

Loading social stream, please wait...

View Full AQST Social Stream

Latest AQST News From Around the Web

Below are the latest news stories about Aquestive Therapeutics Inc that investors may wish to consider to help them evaluate AQST as an investment opportunity.

Blueprint European Approval, And Other News: The Good, Bad And Ugly Of Biopharma

Blueprint gets European Union nod for Ayvakyt Blueprint Medicines Corporation (BPMC) announced receiving the conditional marketing authorization from the European Commission for Ayvakyt. The drug candidate has been indicated as a monotherapy for treating adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring the platelet-derived growth factor receptor...

Avisol Capital Partners on Seeking Alpha | September 29, 2020

Should Aquestive Therapeutics Be Worried About This FDA Response?

No summary available.

24/7 Wall street | September 28, 2020

Aquestive Therapeutics, Inovio Pharmaceuticals among major healthcare premarket losers' pack

Aquestive Therapeutics AQST -32% as FDA rejects Aquestive application for seizure drug. Inovio Pharmaceuticals INO -31% as FDA places partial hold on Inovi

Seeking Alpha | September 28, 2020

FDA responds to Aquestive NDA of cluster seizure drug

Aquestive Therapeutics (AQST) announces that FDA has issued a complete response letter regarding the New Drug Application  for Libervant Buccal Film for management of seizure clusters.FDA cited that, in a study submitted by the company with the NDA, certain weight groups showed a lower drug exposure level than desired.Company intends to...

Seeking Alpha | September 25, 2020

Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters

* Complete Response Letter cites exposure levels (Cmax) in certain weight groups * No additional clinical studies anticipated by Aquestive * No Clinical Safety issues or Non-Clinical Chemistry, Manufacturing and Controls (CMC) issues identified * Conference call and webcast today at 6:30 p.m. ETWARREN

Yahoo Finance | September 25, 2020

Read More 'AQST' Stories Here

AQST Price Returns

1-mo 40.00%
3-mo -6.67%
6-mo 30.49%
1-year -23.20%
3-year N/A
5-year N/A
YTD 15.46%
2019 -7.62%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching AQST

Want to see what other sources are saying about Aquestive Therapeutics Inc's financials and stock price? Try the links below:

Aquestive Therapeutics Inc (AQST) Stock Price | Nasdaq
Aquestive Therapeutics Inc (AQST) Stock Quote, History and News - Yahoo Finance
Aquestive Therapeutics Inc (AQST) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8317 seconds.